864. Rosengren A, Skoog I, Gustafson D and Wilhelmsen L. “Body Mass Index, Other Cardiovascular Risk Factors, and Hospitalization for Dementia.” Archives of Internal Medicine, Volume 165, Number 3, Pages 321-326. FEB 14, 2005. http://archinte.ama-assn.org/cgi/content/abstract/165/3/321
865. Leibson, CL, et al. “The Risk of Dementia among Persons with Diabetes Mellitus: A Population-Based Cohort Study. American Journal of Epidemiology, Volume 145, Number 4, Pages 301-308. 1997. http://aje.oxfordjournals.org/cgi/reprint/145/4/301
866. Janson J, et al. “Increased Risk of Type 2 Diabetes in Alzheimer Disease.” Diabetes, Volume 53, Number 2, Pages 474-481. 2004, http://diabetes.diabetesjournals.org/cgi/content/abstract/53/2/474
867. Miller, M. “Anti-Inflammatory Drugs May Help Reduce Risk of Alzheimer’s disease.” Press Releases. National Institute on Aging, March 10, 1997. http://www.nia.nih.gov/NewsAndEvents/PressReleases/PR1970310AntiInflammatoryDrugs.htm
868. Fishel MA, et al. “Hyperinsulinemia provokes synchronous increases in central inflammation and beta-amyloid in normal adults.” Archives of Neurology. Volume 62, Number 10, Pages 1539-44. October 2005. http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&uid=16216936&cmd=showdetailview&indexed=google
869. Vitek, MP, et al. “Advanced glycation end products contribute to amyloidosis in Alzheimer disease.“ Proceedings of National Academy of Science of the United States of America. Volume 91, Number 11, Pages 4766-4770. May 1994. http://www.pnas.org/cgi/reprint/91/11/4766.pdf
870. Smith MA, et al. “Advanced Maillard reaction end products are associated with Alzheimer disease pathology.” Proceedings of the National Academy of Science of the United States of America, Volume 91, Number 12, Pages 5710–5714. June 7, 1994. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=44066
871. Yan SD, et al. “Amyloid-b peptide–Receptor for Advanced Glycation Endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: A proinflammatory pathway in Alzheimer disease.” Proceedings of the National Academy of Science of the United States of America, Volume 94, Pages 5296–5301, May 1997. http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=24672&blobtype=pdf
872. Obrenovich ME and Monnier VM. “Glycation stimulates amyloid formation.” Science of Aging Knowledge Environment. Volume 2004, Number 2, pe3. January 14, 2004. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=14724325&dopt=Abstract
873. Ahmed N, et al. “Protein glycation, oxidation and nitration adduct residues and free adducts of cerebrospinal fluid in Alzheimer’s disease and link to cognitive impairment.” Journal of Neurochemistry. Volume 92, Number 2, Pages 255–263. January 2005. http://www.blackwell-synergy.com/doi/abs/10.1111/j.1471-4159.2004.02864.x
874. Van der Auwera I, et al. “A ketogenic diet reduces amyloid beta 40 and 42 in a mouse model of Alzheimer’s disease.” Nutrition & Metabolism. Volume 2, Number 28. 2005. http://www.nutritionandmetabolism.com/content/2/1/28
875. Sasaki N, et al. “Advanced Glycation End Products in Alzheimer’s Disease and Other Neurodegenerative Diseases.” American Journal of Pathology. Volume 153, Number 4, Pages 1149–1155. 1998. http://ajp.amjpathol.org/cgi/reprint/153/4/1149.pdf
876. Gustafson D, et al. “An 18-Year Follow-up of Overweight and Risk of Alzheimer Disease.” Archives of Internal Medicine. Volume 163, Number 13, Pages 1524-1528. 2003. http://archinte.ama-assn.org/cgi/content/full/163/13/1524
877. Arvanitakis Z, et al. “Diabetes Mellitus, Dementia, and Cognitive Function in Older Persons.” Journal of Nutrition, Health & Aging, Volume 10, Number 4, Pages 287-291. 2006. http://www.serdi-fr.com/jnha/documents/10_arvanitakis.pdf
878. Yaffe K, et al. “Glycosylated Hemoglobin Level and Development of Mild Cognitive Impairment or Dementia in Older Women.” Journal of Nutrition, Health & Aging, Volume 10, Number 4, Pages 292-295. 2006. http://www.serdi-fr.com/jnha/documents/11_yaffe_c.pdf
879. Luchsinger JA, et al. “Diabetes Mellitus and Risk of Alzheimer’s Disease and Dementia with Stroke in a Multiethnic Cohort.” American Journal of Epidemiology. Volumeume 154, Number 7, Pages 635-641. 2001. http://aje.oxfordjournals.org/cgi/reprint/154/7/635.pdf
880. Geerlings ML, et al. “Endogenous sex hormones, cognitive decline, and future dementia in old men.” Annals of Neurology. Volume 60, Issue 3, Pages 346 – 355. July 24, 2006. http://www3.interscience.wiley.com/cgi-bin/abstract/112728836/ABSTRACT?CRETRY=1&SRETRY=0
881. Whitmer RA, et al. “Obesity in middle age and future risk of dementia: a 27 year Obesity in middle age and future risk of dementia: a 27 year.” British Medical Journal. 2005 June 11 Volume 330, Number 7504, Pages 1360-. June 11, 2005. http://www.bmj.com/cgi/reprint/330/7504/1360
882. Logroscino G, et al. “Prospective study of type 2 diabetes and cognitive decline in women aged 70-81 years.” British Medical Journal.. Volume328 Number 7439, Pages 548-. March 6, 2004. http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=381043
883. Convit A, et al. “Reduced glucose tolerance is associated with poor memory performance and hippocampal atrophy among normal elderly.” Proceedings of the National Academy of Science of the United States of America. Volume 100, Number 4, Pages 2019–2022. February 18, 2003. http://www.pnas.org/cgi/content/full/100/4/2019
884. Solano DC, et al. “Insulin regulates soluble amyloid precursor protein release via phosphatidyl inositol 3 kinase-dependent pathway.” FASEB Journal.. Volume 14, Pages 1015–1022. 2000, http://www.fasebj.org/cgi/content/abstract/14/7/1015
885. Yaffe K, et al. “Glycosylated Hemoglobin Level and Development of Mild Cognitive Impairment or Dementia in Older women.” The Journal of Nutrition, Health & Aging. Volume 10, Number 4, 2006. http://www.serdi-fr.com/jnha/documents/11_yaffe_c.pdf
886. Qin W, et al. “Neuronal SIRT1 Activation as a Novel Mechanism Underlying the Prevention of Alzheimer Disease Amyloid Neuropathology by Calorie Restriction.” Journal of Biological Chemistry. Volume 281, Issue 31, Pages 21745-21754, August 4, 2006. http://www.jbc.org/cgi/reprint/281/31/21745?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&author1=Pasinetti&andorexactfulltext=and&searchid=1&FIRSTINDEX=0&sortspec=relevance&resourcetype=HWCIT
887. Schaefer EJ, et al. “Plasma Phosphatidylcholine Docosahexaenoic Acid Content and Risk of Dementia and Alzheimer Disease. The Framingham Heart Study.” Archives of Neurology. Volume 63, Number 11, Pages 1545-1550. November 2006. http://archneur.highwire.org/cgi/content/full/63/11/1545
888. Craft S, et al. “Insulin dose–response effects on memory and plasma amyloid precursor protein in Alzheimer’s disease: interactions with apolipoprotein E genotype.” Psychoneuroendocrinology. Volume 28, Issue 6, Pages 809-822. August 2003. http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6TBX-482YVNR-4&_user=10&_rdoc=1&_fmt=&_orig=search&_sort=d&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=6c6efb22d5f041b491a1b23a73aa1911
Previous | Study Guide | Next
